Premium
Mohs' micrographic surgery for treatment of basal cell carcinoma of the face——results of a retrospective study and review of the literature
Author(s) -
Smeets N.W.J.,
Kuijpers D.I.M.,
Nelemans P.,
Ostertag J.U.,
Verhaegh M.E.J.M.,
Krekels G.A.M.,
Neumann H.A.M.
Publication year - 2004
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2004.06047.x
Subject(s) - basal cell carcinoma , mohs surgery , medicine , retrospective cohort study , incidence (geometry) , skin cancer , dermatology , treatment modality , surgery , primary treatment , basal cell , carcinoma , cancer , pathology , physics , optics
Summary Background The incidence of skin cancer and especially basal cell carcinoma (BCC) has increased in the last decade and is still increasing. Many treatment modalities can be used to treat BCC; surgical excision is the most frequently used. Mohs' micrographic surgery (MMS) is an advanced excision technique which is often used to treat BCC in the U.S.A. In Europe it is practised less frequently. Objective The aim of this article was to evaluate the efficiency of MMS for the treatment of facial BCC. Methods In a retrospective study recurrence rates after the treatment of facial BCC by MMS were estimated by reviewing the records of all patients with BCCs (620 patients with 720 BCCs) treated by MMS in our department from April 1992 until December 1999. Results The 5‐year recurrence rates estimated from this study were 3·2% for primary BCC and 6·7% for recurrent BCC. Prognostic factors for recurrence are: an aggressive histopathological subtype, more than four Mohs' stages, a large defect size and a recurrent BCC. Conclusion Based on the fact that MMS provides the lowest recurrence rates, it is the treatment of first choice for primary facial BCCs with an aggressive histopathological subtype and for recurrent BCCs in the face.